Drug
Imeroprubart
Imeroprubart: highest development phase Phase 2, developed by Immunovant Sciences GmbH. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Immunovant Sciences GmbH
Trials
| Drug | Phase | Indication |
|---|---|---|
| Imeroprubart NCT07032662 | Phase 2 | Chronic Inflammatory Demyelinating Polyneuropathy |
Latest
No recent events.
Follow Imeroprubart on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.